86 related articles for article (PubMed ID: 9717818)
21. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T; Gaya AM; Dancey G; Stratford MR; Othman S; Sharma SK; Wellsted D; Taylor NJ; Stirling JJ; Poupard L; Folkes LK; Chan PS; Pedley RB; Chester KA; Owen K; Violet JA; Malaroda A; Green AJ; Buscombe J; Padhani AR; Rustin GJ; Begent RH
Clin Cancer Res; 2009 Jul; 15(13):4484-92. PubMed ID: 19549771
[TBL] [Abstract][Full Text] [Related]
22. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
23. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Jayson GC; Mulatero C; Ranson M; Zweit J; Jackson A; Broughton L; Wagstaff J; Hakansson L; Groenewegen G; Lawrance J; Tang M; Wauk L; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
Eur J Cancer; 2005 Mar; 41(4):555-63. PubMed ID: 15737560
[TBL] [Abstract][Full Text] [Related]
24. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Groen HJ; de Vries EG; Wynendaele W; van der Graaf WT; Fokkema E; Lechuga MJ; Poggesi I; Dirix LY; van Oosterom AT
Clin Cancer Res; 2001 Dec; 7(12):3928-33. PubMed ID: 11751484
[TBL] [Abstract][Full Text] [Related]
25. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
26. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
27. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
30. Phase I immunotoxin trial in patients with B-cell lymphoma.
Vitetta ES; Stone M; Amlot P; Fay J; May R; Till M; Newman J; Clark P; Collins R; Cunningham D
Cancer Res; 1991 Aug; 51(15):4052-8. PubMed ID: 1855219
[TBL] [Abstract][Full Text] [Related]
31. Overview of clinical trials employing antibody-targeted superantigens.
Persson B; Persson R; Weiner LM; Alpaugh RK
Adv Drug Deliv Rev; 1998 Apr; 31(1-2):143-152. PubMed ID: 10837622
[TBL] [Abstract][Full Text] [Related]
32. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Gonzalez R; Salem P; Bunn PA; Zukiwski AA; Lamb R; Benjamin RS; Spitler L; Wedel N; Robinson WA
Mol Biother; 1991 Dec; 3(4):192-6. PubMed ID: 1768370
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
[TBL] [Abstract][Full Text] [Related]
35. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization.
Schroff RW; Morgan AC; Woodhouse CS; Abrams PG; Farrell MM; Carpenter BE; Oldham RK; Foon KA
J Biol Response Mod; 1987 Aug; 6(4):457-72. PubMed ID: 3625231
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
38. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
[TBL] [Abstract][Full Text] [Related]
39. A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits.
Ilbäck NG; Persson R; Gunnarsson K; Stålhandske T
J Pharmacol Toxicol Methods; 2002; 48(1):31-9. PubMed ID: 12750039
[TBL] [Abstract][Full Text] [Related]
40. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
Cancer Res; 1985 Nov; 45(11 Pt 2):5910-3. PubMed ID: 4053061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
